Last reviewed · How we verify
low dose diltiazem
low dose diltiazem is a Small molecule drug developed by Seoul National University Hospital. It is currently FDA-approved.
Low dose diltiazem is used to study rate control of atrial fibrillation. It is a small molecule that works by blocking voltage-gated L-type calcium channels.
At a glance
| Generic name | low dose diltiazem |
|---|---|
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low dose diltiazem CI brief — competitive landscape report
- low dose diltiazem updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI
Frequently asked questions about low dose diltiazem
What is low dose diltiazem?
low dose diltiazem is a Small molecule drug developed by Seoul National University Hospital.
Who makes low dose diltiazem?
low dose diltiazem is developed and marketed by Seoul National University Hospital (see full Seoul National University Hospital pipeline at /company/seoul-national-university-hospital).
What development phase is low dose diltiazem in?
low dose diltiazem is FDA-approved (marketed).
Related
- Manufacturer: Seoul National University Hospital — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing